Systemic levels of estrogens and PGE2 synthesis in relation to postmenopausal breast cancer risk

Sangmi Kim, Jeff Campbell, Wonsuk Yoo, Jack A. Taylor, Dale P. Sandler

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Prostaglandin E2 (PGE2) induces aromatase expression in adipose tissue, leading to increased estrogen production that may promote the development and progression of breast cancer. However, few studies have simultaneously investigated systemic levels of PGE2 and estrogen in relation to postmenopausal breast cancer risk. Methods: Here, we determined urinary estrogen metabolites (EM) using mass spectrometry in a case-cohort study (295 incident breast cancer cases and 294 subcohort members), and using linear regression estimated the effect of urinary levels of a major PGE2 metabolite (PGE-M) on EMs. HRs for the risk of developing breast cancer in relation to PGE-M and EMs were compared between Cox regression models with and without mutual adjustment. Results: PGE-M was a significant predictor of estrone (E1), but not estradiol (E2) levels in multivariable analysis. Elevated E2 levels were associated with an increased risk of developing breast cancer [HRQ5vs.Q1, 1.54; 95% confidence interval (CI), 1.01-2.35], and this association remained unchanged after adjustment for PGE-M (HRQ5vs.Q1, 1.52; 95% CI, 0.99-2.33). Similarly, elevated levels of PGE-M were associated with increased risk of developing breast cancer (HRQ4vs.Q1, 2.01; 95% CI, 1.01-4.29), and this association was only nominally changed after consideration of E1 or E2 levels. Conclusions: Urinary levels of PGE-M and estrogens were independently associated with future risk of developing breast cancer among these postmenopausal women. Impact: Increased breast cancer risk associated with PGE-M might not be fully explained by the estrogens-breast cancer association alone but also byadditionaleffects related toinflammation.

Original languageEnglish (US)
Pages (from-to)383-388
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume26
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Dinoprostone
Estrogens
Breast Neoplasms
Confidence Intervals
Aromatase
Estrone
Proportional Hazards Models
Adipose Tissue
Estradiol
Linear Models
Mass Spectrometry
Cohort Studies

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Systemic levels of estrogens and PGE2 synthesis in relation to postmenopausal breast cancer risk. / Kim, Sangmi; Campbell, Jeff; Yoo, Wonsuk; Taylor, Jack A.; Sandler, Dale P.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 3, 01.03.2017, p. 383-388.

Research output: Contribution to journalArticle

Kim, Sangmi ; Campbell, Jeff ; Yoo, Wonsuk ; Taylor, Jack A. ; Sandler, Dale P. / Systemic levels of estrogens and PGE2 synthesis in relation to postmenopausal breast cancer risk. In: Cancer Epidemiology Biomarkers and Prevention. 2017 ; Vol. 26, No. 3. pp. 383-388.
@article{d9a3730a77da4bb2a318659f0605b4fc,
title = "Systemic levels of estrogens and PGE2 synthesis in relation to postmenopausal breast cancer risk",
abstract = "Background: Prostaglandin E2 (PGE2) induces aromatase expression in adipose tissue, leading to increased estrogen production that may promote the development and progression of breast cancer. However, few studies have simultaneously investigated systemic levels of PGE2 and estrogen in relation to postmenopausal breast cancer risk. Methods: Here, we determined urinary estrogen metabolites (EM) using mass spectrometry in a case-cohort study (295 incident breast cancer cases and 294 subcohort members), and using linear regression estimated the effect of urinary levels of a major PGE2 metabolite (PGE-M) on EMs. HRs for the risk of developing breast cancer in relation to PGE-M and EMs were compared between Cox regression models with and without mutual adjustment. Results: PGE-M was a significant predictor of estrone (E1), but not estradiol (E2) levels in multivariable analysis. Elevated E2 levels were associated with an increased risk of developing breast cancer [HRQ5vs.Q1, 1.54; 95{\%} confidence interval (CI), 1.01-2.35], and this association remained unchanged after adjustment for PGE-M (HRQ5vs.Q1, 1.52; 95{\%} CI, 0.99-2.33). Similarly, elevated levels of PGE-M were associated with increased risk of developing breast cancer (HRQ4vs.Q1, 2.01; 95{\%} CI, 1.01-4.29), and this association was only nominally changed after consideration of E1 or E2 levels. Conclusions: Urinary levels of PGE-M and estrogens were independently associated with future risk of developing breast cancer among these postmenopausal women. Impact: Increased breast cancer risk associated with PGE-M might not be fully explained by the estrogens-breast cancer association alone but also byadditionaleffects related toinflammation.",
author = "Sangmi Kim and Jeff Campbell and Wonsuk Yoo and Taylor, {Jack A.} and Sandler, {Dale P.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-16-0556",
language = "English (US)",
volume = "26",
pages = "383--388",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Systemic levels of estrogens and PGE2 synthesis in relation to postmenopausal breast cancer risk

AU - Kim, Sangmi

AU - Campbell, Jeff

AU - Yoo, Wonsuk

AU - Taylor, Jack A.

AU - Sandler, Dale P.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: Prostaglandin E2 (PGE2) induces aromatase expression in adipose tissue, leading to increased estrogen production that may promote the development and progression of breast cancer. However, few studies have simultaneously investigated systemic levels of PGE2 and estrogen in relation to postmenopausal breast cancer risk. Methods: Here, we determined urinary estrogen metabolites (EM) using mass spectrometry in a case-cohort study (295 incident breast cancer cases and 294 subcohort members), and using linear regression estimated the effect of urinary levels of a major PGE2 metabolite (PGE-M) on EMs. HRs for the risk of developing breast cancer in relation to PGE-M and EMs were compared between Cox regression models with and without mutual adjustment. Results: PGE-M was a significant predictor of estrone (E1), but not estradiol (E2) levels in multivariable analysis. Elevated E2 levels were associated with an increased risk of developing breast cancer [HRQ5vs.Q1, 1.54; 95% confidence interval (CI), 1.01-2.35], and this association remained unchanged after adjustment for PGE-M (HRQ5vs.Q1, 1.52; 95% CI, 0.99-2.33). Similarly, elevated levels of PGE-M were associated with increased risk of developing breast cancer (HRQ4vs.Q1, 2.01; 95% CI, 1.01-4.29), and this association was only nominally changed after consideration of E1 or E2 levels. Conclusions: Urinary levels of PGE-M and estrogens were independently associated with future risk of developing breast cancer among these postmenopausal women. Impact: Increased breast cancer risk associated with PGE-M might not be fully explained by the estrogens-breast cancer association alone but also byadditionaleffects related toinflammation.

AB - Background: Prostaglandin E2 (PGE2) induces aromatase expression in adipose tissue, leading to increased estrogen production that may promote the development and progression of breast cancer. However, few studies have simultaneously investigated systemic levels of PGE2 and estrogen in relation to postmenopausal breast cancer risk. Methods: Here, we determined urinary estrogen metabolites (EM) using mass spectrometry in a case-cohort study (295 incident breast cancer cases and 294 subcohort members), and using linear regression estimated the effect of urinary levels of a major PGE2 metabolite (PGE-M) on EMs. HRs for the risk of developing breast cancer in relation to PGE-M and EMs were compared between Cox regression models with and without mutual adjustment. Results: PGE-M was a significant predictor of estrone (E1), but not estradiol (E2) levels in multivariable analysis. Elevated E2 levels were associated with an increased risk of developing breast cancer [HRQ5vs.Q1, 1.54; 95% confidence interval (CI), 1.01-2.35], and this association remained unchanged after adjustment for PGE-M (HRQ5vs.Q1, 1.52; 95% CI, 0.99-2.33). Similarly, elevated levels of PGE-M were associated with increased risk of developing breast cancer (HRQ4vs.Q1, 2.01; 95% CI, 1.01-4.29), and this association was only nominally changed after consideration of E1 or E2 levels. Conclusions: Urinary levels of PGE-M and estrogens were independently associated with future risk of developing breast cancer among these postmenopausal women. Impact: Increased breast cancer risk associated with PGE-M might not be fully explained by the estrogens-breast cancer association alone but also byadditionaleffects related toinflammation.

UR - http://www.scopus.com/inward/record.url?scp=85014519164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014519164&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-16-0556

DO - 10.1158/1055-9965.EPI-16-0556

M3 - Article

VL - 26

SP - 383

EP - 388

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -